<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Robert Hayward et al.|New England Journal of Medicine|2012Cited by 1k
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130H. S. Rugo, Leisha A. Emens, Sherene Loi et al.|Annals of Oncology|2019Cited by 115
Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <scp>SP</scp>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection systemKelly Schats, Mark Kockx|Histopathology|2016Cited by 39
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Bart Neyns, Yanina Jansen et al.|Cancers|2021Cited by 36
Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.Gil Awada, Bart Neyns, Julia Katharina Schwarze et al.|Journal of Clinical Oncology|2020Cited by 3